Faricimab in neovascular age-related macular degeneration: updated week 48 efficacy, safety, and durability in the phase 3 TENAYA and LUCERNE trials

被引：0
|
作者：
London, Nikolas [1 ]
Guymer, Robyn H. [2 ,3 ]
Demetriades, Anna-Maria [4 ]
Ruiz, Carlos Quezada [4 ]
Silverman, David [5 ]
Ives, Jane [5 ]
Basu, Karen [6 ]
Lin, Hugh [4 ]
机构：
[1] Retina Consultants San Diego, San Diego, CA USA
[2] Ctr Eye Res Australia Ltd, Melbourne, Vic, Australia
[3] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Roche Prod Ltd, Welwyn Garden City, Herts, England
[6] Roche Prod Ireland Ltd, Dublin, Ireland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2022年 / 63卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
3120
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis
    Yen, Wei-Ting
    Wu, Chen-Shu
    Yang, Chang-Hao
    Chen, Yi-Hao
    Lee, Cho-Hao
    Hsu, Cherng-Ru
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [22] Efficacy and safety of faricimab every 16 or 12 weeks for neovascular age-related macular degeneration: STAIRWAY phase 2 results
    Danzig, Carl
    Quezada, Carlos
    Basu, Karen
    Grzeschik, Susanna
    Sahni, Jayashree
    Silverman, David
    Osborne, Aaron
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [23] Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis
    Samaca-Samaca, Daniel
    Hernandez-Castillo, Claudia
    Prieto-Pinto, Laura
    Rodriguez, Francisco
    Sardi, Carolina
    Ocampo, Hugo
    Kock, Joshua
    Hernandez, Fabian
    BMJ OPEN OPHTHALMOLOGY, 2024, 9 (01): : 1 - 11
  • [24] Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis
    Wei-Ting Yen
    Chen-Shu Wu
    Chang-Hao Yang
    Yi-Hao Chen
    Cho-Hao Lee
    Cherng-Ru Hsu
    Scientific Reports, 14
  • [25] Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
    Hang, Abraham
    Ngo, Taylor
    Virk, Jaipreet Singh
    Moussa, Kareem
    Moshiri, Ala
    Emami-Naeini, Parisa
    Park, Susanna S.
    CLINICAL OPHTHALMOLOGY, 2024, 18 : 3781 - 3789
  • [26] Faricimab in Previously Treated Eyes With Neovascular Age-Related Macular Degeneration: An Assessment of Durability and Treatment Outcomes
    Shaheen, Abdulla
    Ashkenazy, Noy
    Magraner, Maria
    Patel, Nimesh A.
    Fortun, Jorge
    Rosenfeld, Philip J.
    Schwartz, Stephen G.
    Haddock, Luis J.
    Dubovy, Sander R.
    Sridhar, Jayanth
    Yehoshua, Zohar
    Kovach, Jaclyn L.
    Townsend, Justin H.
    Smiddy, William E.
    Flynn, Harry W., Jr.
    Yannuzzi, Nicolas A.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2024, 55 (09): : 504 - +
  • [27] Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes
    Agostini, Hansjuergen
    Abreu, Francis
    Baumal, Caroline R.
    Chang, Dolly S.
    Csaky, Karl G.
    Demetriades, Anna M.
    Kodjikian, Laurent
    Lim, Jennifer I.
    Margaron, Philippe
    Mones, Jordi M.
    Peto, Tunde
    Ricci, Federico
    Rueth, Matthias
    Singh, Rishi P.
    Stoilov, Ivaylo
    Swaminathan, Balakumar
    Willis, Jeffrey R.
    Westenskow, Peter D.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 262 (11) : 3437 - 3451
  • [28] Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration 52-Week Results of Phase 3 Randomized Controlled Study
    Kunimoto, Derek
    Yoon, Young Hee
    Wykoff, Charles C.
    Chang, Andrew
    Khurana, Rahul N.
    Maturi, Raj K.
    Agostini, Hansjuergen
    Souied, Eric
    Chow, David R.
    Lotery, Andrew J.
    Ohji, Masahito
    Bandello, Francesco
    Belfort, Rubens, Jr.
    Li, Xiao-Yan
    Jiao, Jenny
    Le, Grace
    Schmidt, Werner
    Hashad, Yehia
    OPHTHALMOLOGY, 2020, 127 (10) : 1331 - 1344
  • [29] Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial (vol 67, pg 301, 2023)
    Mori, Ryusaburo
    Honda, Shigeru
    Gomi, Fumi
    Tsujikawa, Akitaka
    Koizumi, Hideki
    Ochi, Haruka
    Ohsawa, Shino
    Okada, Annabelle Ayame
    TENAYA and LUCERNE Investigators
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2023, 67 (03) : 311 - 311
  • [30] Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
    Rush, Ryan B.
    Rush, Sloan W.
    CLINICAL OPHTHALMOLOGY, 2022, 16 : 4041 - 4046
12345